Daebongls.Co.,Ltd.

A078140

KR7078140001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 08/06/2026			5-day change	1st Jan Change
7,950.00 ^KRW	-6.14%		-8.62%	-31.76%

15/05	Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025

Published on 03/23/2026 at 01:14 pm IST

S&P Capital IQ

DAEBONGLS.CO.,LTD.

-6.14%

Daebongls.Co.,Ltd. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported sales was KRW 301.62 million compared to KRW 0.00001 million a year ago. Net income was KRW 10,058.59 million compared to KRW 7,339.46 million a year ago.

Basic earnings per share from continuing operations was KRW 919 compared to KRW 670 a year ago. Diluted earnings per share from continuing operations was KRW 864 compared to KRW 637 a year ago. Basic earnings per share was KRW 919 compared to KRW 670 a year ago.

Diluted earnings per share was KRW 864 compared to KRW 637 a year ago.

Latest news about Daebongls.Co.,Ltd.

15/05	Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
14/11	Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
06/11	Daebongls.Co.,Ltd. announces Annual dividend, payable on April 24, 2026	CI
14/25/14	Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
15/25/15	Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
21/25/21	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
14/24/14	Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
06/24/06	Daebongls.Co.,Ltd. announced that it has received KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation ands another investor	CI
04/24/04	Daebongls.Co.,Ltd. announced that it expects to receive KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation and another investor	CI
14/24/14	Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
16/24/16	Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
20/24/20	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
21/23/21	Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
04/21/04	Tranche Update on Daebongls.Co.,Ltd.'s Equity Buyback Plan announced on February 26, 2021.	CI

Chart Daebongls.Co.,Ltd.

Duration

Period

A078140: Dynamic Chart

Company Profile

DaebongLS Co Ltd is a Korea-based company primarily engaged in the manufacture of pharmaceutical and cosmetic ingredients. The Company operates its business through two segments. The Pharmaceutical Active Ingredient Business segment provides active pharmaceutical ingredients for respiratory treatments, hypertension treatments, and digestive system treatments. The Cosmetic Material Business segment manufactures and sells natural and functional cosmetic ingredients. In addition, the Company provides testing services for materials used on the skin and engages in real estate leasing business. The Company sells its products in domestic and overseas markets.

Employees

131

Sector

Pharmaceuticals

More about the company